



## HPV Vaccination: Basic and Clinical Research

Guest Editors:

**Dr. Alessandro Ghelardi**

Institution of Azienda USL  
Toscana Nord Ovest, 56121 Pisa,  
Italy

**Prof. Dr. Tommaso Simoncini**

Department of Clinical and  
Experimental Medicine,  
Università di Pisa, 56126 Pisa,  
Italy

**Dr. Andrea Ciavattini**

Woman's Health Sciences  
Department, Università  
Politecnica delle Marche, 60121  
Ancona, Italy

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### Message from the Guest Editors

Dear Colleagues,

We are soliciting articles for a Special Issue of the MDPI journal *Vaccines*, entitled “Feature Paper of Vaccines and Women's Health”.

Future studies about HPV vaccination are needed to evaluate clinical protection against disease recurrence in treated patients for all HPV-related diseases, with comprehensive postvaccination surveillance evaluating the reduction of recurrence risk.

Three prophylactic vaccines against HPV infection are available and have been shown to prevent persistent HPV infection and precancerous cervical abnormalities, while therapeutic vaccines are not yet commercially available. Our call is addressed to papers covering any and all of these issues, focusing primarily on HPV vaccination from both clinical and basic research points of view.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)